---
type: research
topic: "Noetik-GSK Deal: Model Licensing vs Drug Asset Economics"
date: 2026-01-09
relevance: SMB, foundation model business models, pharma AI deals
---

# The Noetik-GSK Deal: A New Asset Class in Biotech?

## The Deal

**GSK licenses Noetik's AI foundation models for $50M**

| Term | Detail |
|------|--------|
| Structure | 5-year strategic collaboration + AI model licensing |
| Upfront + Near-term milestones | $50M |
| What GSK Gets | Non-exclusive license to OCTO-VC foundation models (NSCLC, CRC) |
| Subscription Component | Annual licensing fees for ongoing access |
| Data Generation | GSK + Noetik collaborate on bespoke spatial datasets |

**The quote that matters:**

> "This deal defines a new asset class in biotech. We are moving the industry from AI services collaborations to licensing AI infrastructure."
> — Shafique Virani, Noetik CBO

---

## Why This Is Different: Two Business Models Compared

### Traditional Model: "Pay for Drug Assets"

```
┌─────────────────────────────────────────────────────────────────────┐
│                    TRADITIONAL AI PHARMA DEAL                        │
├─────────────────────────────────────────────────────────────────────┤
│                                                                      │
│   PHARMA                          AI COMPANY                         │
│     │                                 │                              │
│     │   Upfront ($50-150M)            │                              │
│     │ ──────────────────────────────► │                              │
│     │                                 │                              │
│     │   Milestones (IND, Ph1, Ph2...) │                              │
│     │ ──────────────────────────────► │  (if drug succeeds)          │
│     │                                 │                              │
│     │   Royalties on drug sales       │                              │
│     │ ──────────────────────────────► │  (if commercialized)         │
│     │                                 │                              │
│     │ ◄────────────────────────────── │                              │
│     │   Drug candidates / targets     │                              │
│                                                                      │
│   VALUE ACCRUES TO: Drug assets                                      │
│   REVENUE TIMING: Back-loaded (5-15 years)                           │
│   RISK: AI company bears drug development risk                       │
│   SUCCESS RATE: ~5% of drugs reach market                            │
│                                                                      │
└─────────────────────────────────────────────────────────────────────┘
```

**Examples:**

| Deal | Upfront | Milestones | Structure |
|------|---------|------------|-----------|
| Recursion-Roche | $150M | Up to $12B (40 programs × $300M) | Per-program milestones |
| Isomorphic-Lilly | $45M | Up to $1.7B | Drug development milestones |
| Isomorphic-Novartis | $37.5M | Up to $1.2B | Drug development milestones |

**The math problem:** If only ~5% of drugs succeed, the AI company's expected value is:
- $150M upfront + (0.05 × $12B) = $150M + $600M = $750M expected value
- But that $600M is spread over 10-15 years and highly uncertain

---

### New Model: "Pay for Model Access"

```
┌─────────────────────────────────────────────────────────────────────┐
│                    NOETIK MODEL LICENSING DEAL                       │
├─────────────────────────────────────────────────────────────────────┤
│                                                                      │
│   PHARMA                          AI COMPANY                         │
│     │                                 │                              │
│     │   Upfront license ($50M)        │                              │
│     │ ──────────────────────────────► │                              │
│     │                                 │                              │
│     │   Annual subscription ($XXM/yr) │                              │
│     │ ──────────────────────────────► │  (recurring)                 │
│     │                                 │                              │
│     │   Data generation fees          │                              │
│     │ ──────────────────────────────► │  (usage-based)               │
│     │                                 │                              │
│     │ ◄────────────────────────────── │                              │
│     │   Model access (API/license)    │                              │
│     │   + Bespoke datasets            │                              │
│                                                                      │
│   VALUE ACCRUES TO: The model itself                                 │
│   REVENUE TIMING: Front-loaded + recurring                           │
│   RISK: Pharma bears drug development risk                           │
│   SUCCESS RATE: N/A — model works regardless of drug outcomes        │
│                                                                      │
└─────────────────────────────────────────────────────────────────────┘
```

---

## The Economic Shift: Drug Assets vs Model Assets

### Revenue Profile Comparison

```
                    CUMULATIVE REVENUE OVER TIME

    $│                                          ┌─── Traditional deal
    B│                                     ····/    (if drugs succeed)
    i│                                ····/
    l│                           ····/
    l│                      ····/
    i│                 ····/        ┌─── Model licensing
    o│            ····/        ────/    (SaaS-like curve)
    n│       ····/        ────/
    s│   ···/        ────/
     │··/       ────/
     │     ────/
     │────/
     └────────────────────────────────────────────► Years
         1    2    3    4    5    6    7    8    9   10

    Legend:
    ···· = Traditional (milestones tied to drug success, back-loaded)
    ──── = Model licensing (subscription + usage, front-loaded)
```

### Risk Transfer

| Aspect | Traditional Deal | Model Licensing |
|--------|------------------|-----------------|
| Who bears drug risk? | AI company (milestones contingent) | Pharma (pays for access regardless) |
| Revenue certainty | Low — depends on 5% success rate | High — subscription is guaranteed |
| Upfront/recurring mix | ~10% upfront / 90% milestone | ~50% upfront / 50% subscription |
| Time to full value | 10-15 years | 3-5 years |
| Scalability | Linear (each drug = new deal) | Platform (same model, many pharmas) |

---

## Illustrative Math: Same Platform, Different Structures

Assume an AI company with a foundation model that 10 pharmas want to use.

### Traditional Structure (Drug Assets)

```
Per pharma:
  Upfront:     $50M
  Milestones:  $500M potential (but 5% probability)
  Expected:    $50M + (0.05 × $500M) = $75M per pharma

10 pharmas × $75M = $750M expected value

But:
  - 90% of the $750M comes in years 5-15
  - High variance (could be $500M or $5B depending on drug outcomes)
  - Each deal is bespoke negotiation
```

### Model Licensing Structure

```
Per pharma:
  Upfront license:     $30M
  Annual subscription: $10M/year × 5 years = $50M
  Total per pharma:    $80M (guaranteed)

10 pharmas × $80M = $800M expected value

And:
  - 100% of revenue is predictable
  - Non-exclusive = can license to all 10 simultaneously
  - Recurring revenue enables higher multiples
  - Same model serves all customers (platform economics)
```

### Valuation Implications

| Metric | Traditional | Model Licensing |
|--------|-------------|-----------------|
| Revenue predictability | Low | High |
| Revenue multiple | 3-5x (biotech) | 8-15x (SaaS) |
| At $100M ARR | $300-500M valuation | $800M-1.5B valuation |

**The insight:** Model licensing turns a biotech company into a software company — with software multiples.

---

## The "New Asset Class" Claim

Noetik claims this is "among the first and largest transactions monetizing a biological foundation model as a scalable enterprise asset."

### What Makes This Different From:

**1. Tempus data licensing?**
- Tempus sells *data access* (raw clinical/genomic data)
- Noetik sells *model access* (trained foundation model)
- The model is the product, not the data

**2. Recursion platform deals?**
- Recursion's deals are still tied to *drug outcomes*
- Noetik's deal is tied to *model access* — pharma pays whether drugs succeed or not

**3. Standard consulting/services?**
- Services = time × people (linear)
- Model licensing = one model × many customers (platform)

---

## Implications for SMB

### If Noetik's Structure Becomes Standard:

| Current SMB Approach | Potential Shift |
|---------------------|-----------------|
| Custom model delivery per pharma | Foundation model license + subscription |
| $4.8M per therapeutic area | $XXM upfront + $YM/year across all TAs |
| Bespoke benchmarking per customer | Standardized model access via API |
| Revenue tied to customer success | Revenue tied to model access |

### SMB's Advantage vs Noetik:

| Dimension | Noetik | SMB |
|-----------|--------|-----|
| Focus | Spatial biology / tumor microenvironment | Multi-modal patient trajectory |
| Data | Spatial transcriptomics (cells) | EHR + imaging + genomics + pathology |
| Use case | Target discovery, trial enrichment | Trial design, enrollment, prognosis |
| Architecture | Virtual cell models | JEPA world model |
| Stage | Research/preclinical | Clinical/development |

**Key question:** Can SMB shift from "custom model delivery" to "foundation model licensing"?

---

## The Deal Landscape (Visual)

```
                        VALUE OF WHAT'S SOLD
                              │
              Drug Assets     │      Model Access
              (outcomes)      │      (infrastructure)
                              │
    ┌─────────────────────────┼─────────────────────────┐
    │                         │                         │
    │   RECURSION             │                         │
H   │   • $12B Roche deal     │                         │
I   │   • Milestones tied     │                         │
G   │     to drug success     │                         │
H   │                         │                         │
    │   ISOMORPHIC            │         NOETIK ◄────────┼── NEW
D   │   • $3B Lilly/Novartis  │         • $50M GSK      │
E   │   • Drug development    │         • Subscription  │
A   │     milestones          │         • Model license │
L   │                         │                         │
    │                         │                         │
V   │                         │         SMB?            │
A   │                         │         • $4.8M Sanofi  │
L   │                         │         • Custom model  │
U   │                         │         • Could shift → │
E   │                         │                         │
    │   TEMPUS                │                         │
L   │   • Data licensing      │                         │
O   │   • Services            │                         │
W   │                         │                         │
    │                         │                         │
    └─────────────────────────┴─────────────────────────┘
```

---

## Open Questions

1. **Is $50M the right anchor?** How does this scale — is $50M the floor or the ceiling for model licensing?

2. **Non-exclusive = commoditization risk?** If GSK's license is non-exclusive, what prevents Noetik from licensing to all pharmas and eroding GSK's advantage?

3. **Subscription pricing?** What's the annual fee? If it's $10M/year, that's $50M over 5 years on top of upfront — $100M total.

4. **Can SMB replicate?** SMB is further downstream (clinical vs preclinical). Does model licensing work for trial design / enrollment prediction?

5. **Pharma adoption?** Will other pharmas follow GSK, or is this a one-off? If 5+ pharmas sign model licenses in 2026, it's a trend.

---

## Sources

- [Fierce Biotech: GSK inks a model deal in $50M bet on Noetik's cancer AI platform](https://www.fiercebiotech.com/biotech/gsk-inks-model-deal-50m-bet-noetiks-cancer-ai-platform)
- [Endpoints News: GSK to pay $50M to use Noetik's AI cancer models](https://endpoints.news/gsk-noetik-sign-cancer-deal-on-ai-virtual-cell-models/)
- [Noetik Website](https://www.noetik.ai/)
- [Recursion-Roche Deal](https://ir.recursion.com/news-releases/news-release-details/recursion-announces-transformational-collaboration-roche-and)
- [Isomorphic-Lilly/Novartis Deals](https://www.isomorphiclabs.com/articles/isomorphic-labs-kicks-off-2024-with-two-pharmaceutical-collaborations)

---

*Research completed 2026-01-09*
